2025 was a challenging year for Corcept Therapeutics Inc. (CORT), as its lead drug candidate, Relacorilant, was denied FDA approval for hypertension secondary to hypercortisolism, abruptly disrupting its near-term growth story. Shares, which had climbed past $100 early in the year, fell to about $35 by year-end, raising investor concerns.
Fast forward to today, and the same drug candidate has secured FDA approval for an alternate indication, sparking renewed optimism. Could this approval mark a turning point for Corcept and its stock?
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.